Guidelines and Consensus
Interpretation of 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer: era of individualized precision medicine
Ni Wenjing, Xu Shuhang, Liu Chao
Published 2022-03-20
Cite as Int J Endocrinol Metab, 2022, 42(2): 161-164. DOI: 10.3760/cma.j.cn121383-20211101-11002
Abstract
In 2021, American Thyroid Association (ATA) updated guideline for management of patients with anaplastic thyroid cancer (ATC), which entails 31 recommendations and 16 good practice statements. With substantial improvement of clinical research during last decade, the new guideline put a high value of molecular testing, targeted therapy and recognized the clinic value of immunotherapy in ATC management. ATC management has entered the era of individualized precision medicine. In a way that interpreting the highlights of the new guideline, we confirm the great progress in current ATC diagnosis and treatment as well as point out some unresolved problems, aiming to attain multidisciplinary team engagement and coordination so as to help clinicians further improve the management of ATC.
Key words:
Anaplastic thyroid cancer; Molecular testing; Targeted therapy; Precision medicine
Contributor Information
Ni Wenjing
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
Xu Shuhang
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
Liu Chao
Department of Endocrinology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China
